Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
A Study of NB003 in Patients With Advanced Malignancies
2022-502401-15-00Phase 2Completed
- Sponsor
- Ningbo NewBay Technology Development Co., Ltd.
- Start
- Jun 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 6
01
Overview
Phase 2, open-label, single-arm trial of betacetylmethadol in gastrointestinal stromal tumor (GIST), Nonhematologic neoplasms and melanoma, sponsored by Ningbo NewBay Technology Development Co., Ltd. Started Jun 2023; status: completed.
02
Drugs
betacetylmethadol
03
Conditions
gastrointestinal stromal tumor (GIST)Nonhematologic neoplasmsmelanoma
Beyond the preview
Go deeper on 2022-502401-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502401-15-00.